Abdulla A. Damluji/X
Nov 18, 2025, 08:52
Aspirin or P2Y12 Monotherapy?
Abdulla A. Damluji, Director of the Cardiovascular Center on Aging at Cleveland Clinic, has shared a post on X:
“Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?
Very nice review.”
Stay informed with Hemostasis Today.
-
Feb 23, 2026, 15:20Rabab Al Dawood: Moderating the Coagulation and Hemostasis Session at the ISLH 1st Joint Conference
-
Feb 23, 2026, 15:16Amira Khater: Key Updates on Pulmonary Embolism Management from AHA and ACC Guidelines
-
Feb 23, 2026, 14:45Stacey McGeown: Rare Disease Awareness Day at QUB Marks the Start of Rare Disease Month
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC